Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤C-BEYOND met primary and secondary endpoints; BEM/RZR was non-inferior to Epclusa
- ➤BEM/RZR achieved 93.91% SVR versus Epclusa’s 94.75% at Week 24
- ➤C-FORWARD topline results expected early 2027; NDA filing targeted for mid-2027
- ➤Hercules Capital facility provides up to $200 million; Atea drew $65 million
- ➤Third-quarter net loss narrowed to $32.2 million from $42.0 million year over year
Expert Statements
Jean-Pierre Sommadossi, Chief Executive Officer and Founder of Atea Pharmaceuticals
“The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers.”
Jean-Pierre Sommadossi, Chief Executive Officer and Founder of Atea Pharmaceuticals
“Healthcare systems are increasingly focusing on test-and-treat strategies as integral to enhanced HCV elimination efforts. BEM/RZR’s profile is uniquely suited to meet the needs of patients and providers embracing this model.”
Jean-Pierre Sommadossi, Chief Executive Officer and Founder of Atea Pharmaceuticals
“We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV”
Jean-Pierre Sommadossi, Chief Executive Officer and Founder of Atea Pharmaceuticals
“We are also rapidly advancing our HEV program and successfully completed the single ascending dose portion of our Phase 1 study for AT-587. We are now conducting the multiple ascending dose portion of this study and preparing for an anticipated proof-of-concept study in 2027”
Jean-Pierre Sommadossi, Chief Executive Officer and Founder of Atea Pharmaceuticals
“There is a significant unmet need for HEV treatment among people who are immunocompromised and at high risk. We are building the foundation for what we currently anticipate may be a first-in-class direct-acting antiviral for chronic HEV and are excited about the potential of AT-587 to provide an important new treatment option for at-risk HEV patients.”
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection
Phase 3 C-FORWARD Trial for HCV on Track for Topline Results in Early 2027
Get started
Create a free account to read the full story.